CN107865862A - Apigenin is preparing the application in treating rhinitis medicine - Google Patents
Apigenin is preparing the application in treating rhinitis medicine Download PDFInfo
- Publication number
- CN107865862A CN107865862A CN201610850113.XA CN201610850113A CN107865862A CN 107865862 A CN107865862 A CN 107865862A CN 201610850113 A CN201610850113 A CN 201610850113A CN 107865862 A CN107865862 A CN 107865862A
- Authority
- CN
- China
- Prior art keywords
- apigenin
- rhinitis
- medicine
- compound
- preparing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A kind of Apigenin for treating immune inflammation, immune inflammation disease drug is treated for preparing, is particularly suitable for use in and prepares the medicine for the treatment of rhinitis, it is clear and definite by the use of teldane and diclofenac sodium as control, Apigenin curative effects.Purposes of the Apigenin of the present invention in treatment rhinitis medicine is prepared belongs to first public, because framework types belong to brand-new framework types, and it is treated rhinitis activity and is unexpectedly strong, in the absence of the possibility that any enlightenment is provided by other compounds, possess prominent substantive distinguishing features, while obviously there is significant progress for the preventing and treating of rhinitis.
Description
Technical field
The present invention relates to compound Apigenin new application, more particularly to Apigenin is in treatment rhinitis medicine is prepared
Application.
Background technology
Rhinitis is common clinical and frequently-occurring disease, and the generation of rhinitis is mainly relevant with allergic reaction, belongs to immune inflammation
Category.At present, rhinitis is treated mainly using antiallergics such as antihistamine drug or tranilast, Ketotifen such as teldanes
Thing, these medicines are poor or invalid to the chronicity and recurrent exerbation curative effect of rhinitis.Therefore, definite ingredients, quality controllable and peace
Complete efficient micromolecular compound has potential value in terms for the treatment of of rhinitis medicine is developed.
Compound Apigenin of the present invention is one and delivers within 2007 (Ebenezer de Mello Cruz, et
al.,Leishmanicidal activity of Cecropia pachystachya flavonoids:Arginase
inhibition and altered mitochondrial DNA arrangement.Phytochemistry,89(2013)
71-77.) noval chemical compound, the compound possess brand-new framework types (Ebenezer de Mello Cruz, et al.,
Leishmanicidal activity of Cecropia pachystachya flavonoids:Arginase
inhibition and altered mitochondrial DNA arrangement.Phytochemistry,89(2013)
71-77.), belong to first public for purposes of the Apigenin of the present invention in treatment rhinitis medicine is prepared, due to category
In brand-new structure type, and it is unexpectedly strong for treating the activity of rhinitis, is provided in the absence of by other compounds
The possibility of any enlightenment, possess prominent substantive distinguishing features, while obviously there is significant progress for the preventing and treating of rhinitis.
The content of the invention
It is an object of the invention to do not find that it has the report of anti-rhinitis activity in being studied according to existing Apigenin
Present situation, there is provided applications of the Apigenin in anti-rhinitis medicament thing is prepared.
The compound Apigenin, shown in structure such as formula (I)：
The Apigenin is preparing the application in treating rhinitis medicine, rhinitis rat caused by Apigenin reduces histamine
Sneeze number.
One kind treats rhinitis medicine, is that active component addition auxiliary material is prepared by Apigenin, preparation method is to take 5 grams
Compound Apigenin, 195 grams of dextrin is added, mixed, Conventional compression is made 1000.
One kind treats rhinitis medicine, is that active component addition auxiliary material is prepared by Apigenin, preparation method is to take 5 grams
Compound Apigenin, 195 grams of starch is added, mixed, it is encapsulated to be made 1000.
Apigenin 10,20mg/kg are administered orally, and nose is scratched to rat caused by antigen (ovalbumin) and histamine, is beaten
Sneeze is reacted and the rise of nasal cavity vasopermeability is inhibited, therefore, available for the medicine for preparing treatment rhinitis.
Purposes of the Apigenin in treatment rhinitis medicine is prepared belongs to first public, because framework types belong to brand-new
Framework types, and it is treated rhinitis activity and is unexpectedly strong, in the absence of the possibility that any enlightenment is provided by other compounds,
Possess prominent substantive distinguishing features, while obviously there is significant progress for the preventing and treating of rhinitis.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by specific reality
Any restrictions of example are applied, but are defined in the claims.
Embodiment
Compound Apigenin involved in the present invention preparation method referring to document (Ebenezer de Mello Cruz,
et al.,Leishmanicidal activity of Cecropia pachystachya flavonoids:Arginase
inhibition and altered mitochondrial DNA arrangement.Phytochemistry,89(2013)
71–77.)
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by specific reality
Any restrictions of example are applied, but are defined in the claims.
Embodiment 1：The preparation of compound Apigenin tablets involved in the present invention：
5 g of compound Apigenin are taken, add 195 grams of dextrin, are mixed, conventional tablet presses are made 1000.
Embodiment 2：The preparation of compound Apigenin capsules involved in the present invention：
5 g of compound Apigenin are taken, add 195 grams of starch, are mixed, it is encapsulated to be made 1000.
Its pharmaceutical activity is further illustrated below by pharmacodynamic experiment.
Experimental example 1, Apigenin of the present invention cause the influence of rat allergic rhinitis to ovalbumin
Male SD rat, 180~220g of body weight, be injected intraperitoneally ovalbumin 1mg and gel aluminum hydroxide 10mg, thereafter every
Day injection 1 time, totally 7 times.Began from the 14th day, instill 1mg/ml ovalbumin normal saline solutions in the nasal cavity of rat both sides daily
10ul, totally 7 times.Last observes the number of rat sneezing and wiping nose in 30 minutes at once after instiling, trial drug is in white of an egg egg
White last is orally given for 1 hour before instiling.
1 Apigenin of the present invention of table causes the influence (x ± SD) of rat allergic rhinitis to ovalbumin
Compared with control group, * * P<0.01*P<0.05
From table 1, the spray of allergic rhinitis rat caused by Apigenin (10,20mg/kg) substantially suppresses ovalbumin
Sneeze and scratch nose reaction.Significant inhibitory action is also presented in teldane 10mg/kg.
The influence of experimental example 2, Apigenin of the present invention to rat rhinitis caused by histamine
Male SD rat, 180~220g of body weight, orally give after trial drug 1 hour, 1M histamine is instilled in the nasal cavity of both sides
Normal saline solution 10ul, observe the number of rat sneezing and wiping nose in 30 minutes.
2 Apigenin of the present invention of table causes the influence (x ± SD) of rat rhinitis to histamine
Compared with control group, * * P<0.01*P<0.05
From table 2, the sneeze time of rhinitis rat caused by Apigenin (10,20mg/kg) of the present invention significantly reduces histamine
Number, it is in suppression trend to scratching nose reaction.Teldane 10mg/kg is in then significant inhibitory action.
Conclusion：Apigenin is administered orally, and nose, sneezing are scratched to rat caused by antigen (ovalbumin) and histamine instead
Should be inhibited, therefore, available for the medicine for preparing treatment rhinitis.
Claims (4)
- Applications of the 1.Apigenin in rhinitis medicine is treated, shown in the compound Apigenin structures such as formula (I)：
- 2. applications of the Apigenin as claimed in claim 1 in rhinitis medicine is treated, it is characterised in that Apigenin reduction groups The sneeze number of rhinitis rat caused by amine.
- 3. one kind treats rhinitis medicine, it is characterised in that the Apigenin as described in claim 1 is that active component adds auxiliary material system Standby to form, preparation method adds 195 grams of dextrin, mixed, Conventional compression is made 1000 to take 5 g of compound Apigenin.
- 4. one kind treats rhinitis medicine, it is characterised in that the Apigenin as described in claim 1 is that active component adds auxiliary material system Standby to form, preparation method adds 195 grams of starch, mixing is encapsulated to be made 1000 to take 5 g of compound Apigenin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610850113.XA CN107865862A (en) | 2016-09-25 | 2016-09-25 | Apigenin is preparing the application in treating rhinitis medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610850113.XA CN107865862A (en) | 2016-09-25 | 2016-09-25 | Apigenin is preparing the application in treating rhinitis medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107865862A true CN107865862A (en) | 2018-04-03 |
Family
ID=61751705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610850113.XA Pending CN107865862A (en) | 2016-09-25 | 2016-09-25 | Apigenin is preparing the application in treating rhinitis medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107865862A (en) |
-
2016
- 2016-09-25 CN CN201610850113.XA patent/CN107865862A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005110431A1 (en) | Herbal product containing glucosamine | |
| CN107865862A (en) | Apigenin is preparing the application in treating rhinitis medicine | |
| CN107865846A (en) | Isovitexin is preparing the application in treating rhinitis medicine | |
| CN103585150B (en) | Use of Nitrosporeusines A in drugs for treating rhinitis | |
| WO2008109521A2 (en) | Method of treatment using atranorin | |
| EP3977989A1 (en) | Composition for the treatment of novel corona virus disease (covid-19) | |
| CN105362274A (en) | Application of biscarpamontamine A in preparation of rhinitis pharmaceuticals | |
| EP2727595B1 (en) | Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation | |
| CN103494826B (en) | The application of Phyllanthoid A in preparation treatment rhinitis medicine | |
| CN106491617A (en) | Applications of the Friedolanostanes in treatment rhinitis medicine is prepared | |
| CN103463007A (en) | Application of racemosins A in preparation of medicine treating rhinitis | |
| CN106389404A (en) | Applications of Linderolide H in preparing medicines for treating rhinitis | |
| CN106551936A (en) | One kind treats rhinitis medicine and its application | |
| CN105287545A (en) | Applications of Strynuxlines A in preparation of rhinitis treatment drugs | |
| CN105456246A (en) | Application of Lathyranone A in preparation of drug for treating rhinitis | |
| CN108992549A (en) | A kind of pharmaceutical composition and preparation method thereof, application | |
| CN103330712A (en) | Application of Myriberine A in preparation of a medicine for treating rhinitis | |
| CN103271932A (en) | Applications of compound in preparing drug for treating rhinitis | |
| CN103751170B (en) | The application of Trigoxyphin K in treatment rhinitis medicine | |
| CN105287495A (en) | Application of Sphenostylisins C in preparation of drugs used for treating rhinitis | |
| CN102872034A (en) | Application of Gypensapogenin B in medicaments for treating rhinitis | |
| CN103462951B (en) | Application of scopariusins in preparation of medicine treating or preventing canker sore | |
| CN105125533A (en) | Medicine for treating rhinitis and application thereof | |
| CN103585152A (en) | Application of Caesanines D in medicament for treating rhinitis | |
| CN103393699B (en) | The application of Chukrasone A in preparation treatment rhinitis medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180403 |
|
| WD01 | Invention patent application deemed withdrawn after publication |